13 listed sites: United States (13) - 15 Nov `24TEV-53408 antibody treatment for nonsegmental vitiligo

TEV-53408 antibody treatment for nonsegmental vitiligo

Official title: A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo

Status: Closed to new participants

Description:

Teva Branded Pharmaceutical Products R&D LLC plans to enroll about 66 participants. The experimental antibody blocks IL-15, an immune signal that helps pigment-destroying T cells survive. Researchers hope it will reduce the immune attack on melanocytes and allow skin color to return. Possible risks include injection or infusion reactions, headache, and infections; longer-term risks are still being studied. People ages 18 to 75 may qualify. The study is underway but is no longer accepting new participants.

Start date: November 11, 2024

Completion date: January 31, 2029

Organizer: Teva Branded Pharmaceutical Products R&D LLC

Contact: Teva Medical Expert, MD

Link: https://clinicaltrials.gov/study/NCT06625177

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference TEV-53408 antibody treatment for nonsegmental vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions

  • Diabetes and Vitiligo: Is There a Connection?

    Yes, there appears to be a real connection between vitiligo and diabetes, especially type 1 diabetes. A recent study using UK Biobank data also found an association with type 2 ...

  • Red Wine and Vitiligo

    Recent research has explored whether moderate red wine consumption might influence vitiligo risk, especially through genetic studies and large population data. What the Genetic ...

  • Белые пятна на теле? Витилиго?

    Гид по Витилиго — ваш компас в лабиринте загадочной болезни и непростых решений. Здесь всё по-честному, по делу и на понятном языке. Вы найдёте здесь: Объяснения, что происходи...